Longeveron Presents at the Roth Conference
MIAMI — Longeveron Inc. (NASDAQ: LGVN), a pioneering company in the field of regenerative medicine, is set to make its presence known at the anticipated Roth Conference. This year, the 37th Annual Roth Conference will take place over two exciting days, showcasing cutting-edge advancements in the healthcare sector.
Event Details
During the conference, Longeveron will participate in a fireside chat where they will share insights about their innovative therapies aimed at tackling serious health challenges associated with aging. This engaging presentation is scheduled for Tuesday of the conference, with the specific details laid out as follows:
Date and Time
The chat will occur on March 18, allowing attendees to gain valuable knowledge about Longeveron's contributions to regenerative medicine. The event is set to start at 9:00 a.m. PT, lasting for approximately 25 minutes.
Accessing the Presentation
For those interested in following Longeveron's presentation, the webcast will be available in the Events and Presentations section on their official website. Should you miss the live session, worries not! A replay will be accessible for up to 90 days after the conference, ensuring that everyone can benefit from the insights shared.
About Longeveron Inc.
Longeveron is dedicated to advancing the field of regenerative medicine. Their flagship product, Lomecel-B™, is a groundbreaking allogeneic medicinal signaling cell therapy sourced from the bone marrow of young, healthy adult donors. This innovative therapy showcases multiple mechanisms of action, including promoting vascular health, enhancing tissue repair, and combating inflammation, making it versatile for a wide range of medical applications.
Pipeline Indications
The company is currently focused on three primary pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and aging-related frailty. Each of these conditions represents a significant unmet medical need, and Longeveron’s efforts aim to introduce robust solutions for patients facing these challenges.
Recognitions from the FDA
Lomecel-B™ has garnered critical recognition from the FDA, receiving several designations that underscore its potential impact in medicine. For the HLHS program, it achieved Orphan Drug, Fast Track, and Rare Pediatric Disease designations. Meanwhile, the Alzheimer’s disease program has been awarded both the Regenerative Medicine Advanced Therapy (RMAT) designation and the Fast Track designation, illustrating the urgency and promise of this research.
Connect with Longeveron
For additional information about Longeveron, interested parties can explore their initiatives on their official website. Whether you are an investor, a healthcare professional, or someone with a keen interest in innovative healthcare solutions, Longeveron encourages you to stay informed. You can also follow Longeveron on popular social media platforms like LinkedIn, X, and Instagram to keep up with their latest updates.
Contact Information
For media inquiries or investor relations needs, individuals can reach out to Derek Cole at Investor Relations Advisory Solutions. He is available for any questions that you may have, and you can contact him via email at derek.cole@iradvisory.com.
Frequently Asked Questions
What is the focus of Longeveron Inc.?
Longeveron Inc. focuses on developing regenerative therapies for life-threatening and chronic conditions associated with aging.
When is Longeveron scheduled to present at the Roth Conference?
The company is set to present on March 18 at 9:00 a.m. PT.
How can I access Longeveron's conference presentation?
The webcast for the presentation will be available on Longeveron's website in the Events and Presentations section.
What therapy is Longeveron's lead product?
The lead product is Lomecel-B™, an innovative cell therapy designed to address various medical conditions.
What recognitions has Lomecel-B™ received from the FDA?
Lomecel-B™ has received multiple FDA designations including Orphan Drug and Fast Track status for its programs in HLHS and Alzheimer's disease.
